Skip to content

The Impact of Goal-Directed Fluid Therapy Based on Plasma Osmolarity on the Prognosis of Patients Undergoing Major Thoracoabdominal Surgery

The Impact of Goal-Directed Fluid Therapy Based on Plasma Osmolarity on the Prognosis of Patients Undergoing Major Thoracoabdominal Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500106465
Enrollment
Unknown
Registered
2025-07-24
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with esophageal cancer, stomach cancer, colorectal cancer, and liver cancer

Interventions

Control group:Target-directed fluid therapy infusion Ringer test fluid maintenance
Treatment group:On the basis of goal-directed fluid therapy, it intervenes in plasma osmolarity

Sponsors

Chongqing University Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients or their family members agree and sign the informed consent form; 2.Patients aged 18-75 years old, ASA grade ?, grade ?; 3.Scheduled for major abdominal surgery (tumor resection, level-four surgery), including radical surgery for esophageal cancer, gastric cancer, colorectal cancer, and liver cancer; 4.Preoperative cardiac and pulmonary function is normal or mildly impaired (ejection fraction EF > 45%, arterial blood gas analysis with oxygen partial pressure > 70 mmHg, and normal carbon dioxide partial pressure).

Exclusion criteria

Exclusion criteria: 1.Patients undergoing emergency surgery; 2.Preoperative severe cardiac and pulmonary insufficiency, liver and kidney dysfunction (bilirubin > 2 times the normal value, transaminase > 3 times the normal value, creatinine > 117 umol/L, creatinine clearance rate > 50%), coagulation dysfunction (prolonged T > 3 seconds), fever, infection, etc. 3.Patients who have already undergone fluid management interventions preoperatively; 4.Participating in other clinical trials;

Design outcomes

Primary

MeasureTime frame
Plasma osmolarity;

Secondary

MeasureTime frame
Stroke Volume Variation;

Countries

China

Contacts

Public ContactHaijian Shen

Chongqing University Cancer Hospital

shenhj17@126.com+86 23 65075689

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026